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  Twenty patients with benign prostatic hypertrophy were treated with an anti－androgenic
agent， ch夏ormadinone acetate（Prostal⑩），50 mg dai正y for 3 months． As a contro正，20 patients
with prostatic hypertrophy were treated with Eviprostat which was a non－hormonal remedy
consisting of plant extracts 6 tablets daily for the same duration．
  Subjective symptoms of i4 patients （70％） in the Eviprostat group and 18 cases （90％）
in the Prostal group were improved significant！y． Although there were no significant changes
in size or weight of the prostate after 3 months in the patients in the Eviprostat group as
measured by transrectal ultrasonotomography， remarkable reduction in size and weight of
the prostate was observed after 3 months in 11 patients （55％） in the ？rostal group． Four
cases eomplained of impotency during Prostal treatment， but no other side effects to the
hepatic andfor renal functions were observed．
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   （20例）
56 一一 60 2 3
61 N 65 2 2
66 一 70 7 8
71 一 75 4 4
76 一一 80 4 3
81 一 85 o o
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   （％）
計
夜間頻尿 17 ｛85） 2 （10） t （5） 20
排尿困難 S5 （75） 4 （20） 1 〈5） 20
尿線細小 10 （50） lo （se） o （o） 20
残 尿 感 13 （65） 7 （35） o （o） 20
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Table 4． CMA投与による超音波像の変化
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iig．3．最大轍径の変化
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